Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyper-CVAD Plus Imatinib for Ph+ ALL
NCT00038610Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2001
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Response To Induction Therapy With Hyper-CVAD Plus Imatinib Mesylate at 6 months and Disease-Free Survival Rate at 5 years. Started Mar 2001; status: completed.
02
Drugs
03
Conditions
Philadelphia chromosome-positive acute lymphoblastic leukemia
Beyond the preview
Go deeper on NCT00038610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00038610.